Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Oliver

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
American Journal of Clinical Oncology|May 29, 2015
Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain MetastasesKirtesh R Patel, Sana Shoukat, Daniel E Oliver, et al.
Neuro-Oncology|May 28, 2015
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastasesKirtesh R Patel, David H Lawson, Ragini R Kudchadkar, et al.
Frontiers in Oncology|March 21, 2022
Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer TherapiesSebastian Rubino, Daniel E Oliver, Nam D Tran, et al.
American Journal of Clinical Oncology|November 26, 2019
Novel Dose Escalation Approaches for Stereotactic Body Radiotherapy to Adrenal Oligometastases: A Single-Institution ExperienceNicholas B Figura, Daniel E Oliver, Homan Mohammadi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 16, 2017
Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the LungZhigang Yuan, Allison Fromm, Kamran A Ahmed, et al.
The Lancet. Oncology|August 7, 2021
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysisJacob G Scott, Geoffrey Sedor, Patrick Ellsworth, et al.
Journal of Neuro-Oncology|July 25, 2023
Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastasesVaseem M Khatri, Matthew N Mills, Daniel E Oliver, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|August 13, 2025
Evaluation of two treatment planning systems for single isocenter multiple metastases stereotactic radiosurgery treatment planning and deliveryChristopher J Tichacek, Daniel Opp, William Johansson, et al.
American Journal of Clinical Oncology|March 29, 2020
Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain MetastasesAustin J Sim, Kamran A Ahmed, Andrew Keller, et al.
Clinical Lung Cancer|May 8, 2024
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy AloneMatthew N Mills, Akihiro Uno, Pinxue Li, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
American Journal of Clinical Oncology|May 29, 2015
Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain MetastasesKirtesh R Patel, Sana Shoukat, Daniel E Oliver, et al.
Neuro-Oncology|May 28, 2015
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastasesKirtesh R Patel, David H Lawson, Ragini R Kudchadkar, et al.
Frontiers in Oncology|March 21, 2022
Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer TherapiesSebastian Rubino, Daniel E Oliver, Nam D Tran, et al.
American Journal of Clinical Oncology|November 26, 2019
Novel Dose Escalation Approaches for Stereotactic Body Radiotherapy to Adrenal Oligometastases: A Single-Institution ExperienceNicholas B Figura, Daniel E Oliver, Homan Mohammadi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 16, 2017
Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the LungZhigang Yuan, Allison Fromm, Kamran A Ahmed, et al.
The Lancet. Oncology|August 7, 2021
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysisJacob G Scott, Geoffrey Sedor, Patrick Ellsworth, et al.
Journal of Neuro-Oncology|July 25, 2023
Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastasesVaseem M Khatri, Matthew N Mills, Daniel E Oliver, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|August 13, 2025
Evaluation of two treatment planning systems for single isocenter multiple metastases stereotactic radiosurgery treatment planning and deliveryChristopher J Tichacek, Daniel Opp, William Johansson, et al.
American Journal of Clinical Oncology|March 29, 2020
Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain MetastasesAustin J Sim, Kamran A Ahmed, Andrew Keller, et al.
Clinical Lung Cancer|May 8, 2024
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy AloneMatthew N Mills, Akihiro Uno, Pinxue Li, et al.
Pageof 5